121 related articles for article (PubMed ID: 15368437)
1. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
[TBL] [Abstract][Full Text] [Related]
2. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
3. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy.
Schott E; Witt H; Neumann K; Bergk A; Halangk J; Weich V; Müller T; Puhl G; Wiedenmann B; Berg T
J Viral Hepat; 2008 Jan; 15(1):71-8. PubMed ID: 18088248
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary study on the association of chemokine RANTES gene polymorphisms with HIV-1 infection in Chinese Han population].
Liu XL; Wang FS; Jin L; Liu MX; Xu DZ
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):971-5. PubMed ID: 14687494
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
[TBL] [Abstract][Full Text] [Related]
6. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
[TBL] [Abstract][Full Text] [Related]
8. Association of RANTES -403 G/A, -28 C/G and In1.1 T/C polymorphism with HIV-1 transmission and progression among North Indians.
Rathore A; Chatterjee A; Sivarama P; Yamamoto N; Singhal PK; Dhole TN
J Med Virol; 2008 Jul; 80(7):1133-41. PubMed ID: 18461620
[TBL] [Abstract][Full Text] [Related]
9. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K
Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes.
Zhernakova A; Alizadeh BZ; Eerligh P; Hanifi-Moghaddam P; Schloot NC; Diosdado B; Wijmenga C; Roep BO; Koeleman BP
Genes Immun; 2006 Oct; 7(7):544-9. PubMed ID: 16855620
[TBL] [Abstract][Full Text] [Related]
12. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients.
Shalaby SM; Radwan MI; Abdelazim S; Nafee AM
Cell Immunol; 2012; 276(1-2):110-3. PubMed ID: 22594992
[TBL] [Abstract][Full Text] [Related]
14. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
Nattermann J; Vogel M; Nischalke HD; Danta M; Ahlenstiel G; Michalk M; Sauerbruch T; Rockstroh JK; Spengler U;
AIDS; 2008 Jul; 22(11):1287-92. PubMed ID: 18580607
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of chronic hepatitis C virus genotypes among patients between 21 to 65 years old in Puerto Rico.
Rodríguez-Pérez F; Suárez-Pérez E; Alvarez-Rohena M; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):49-56. PubMed ID: 16929587
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML
Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377
[TBL] [Abstract][Full Text] [Related]
18. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.
Mueller T; Mas-Marques A; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Wiedenmann B; Schreier E; Berg T
J Hepatol; 2004 Oct; 41(4):652-8. PubMed ID: 15464247
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
20. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
